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https://doi.org/10.1186/s12917-019-1909-6RESEARCH ARTICLE Open AccessCharacterization of antiviral T cell responses
during primary and secondary challenge of
laboratory cats with feline infectious
peritonitis virus (FIPV)
Farina Mustaffa-Kamal1,2*, Hongwei Liu3, Niels C. Pedersen1,3 and Ellen E. Sparger1*Abstract
Background: Feline infectious peritonitis (FIP) is considered highly fatal in its naturally occurring form, although up
to 36% of cats resist disease after experimental infection, suggesting that cats in nature may also resist development of
FIP in the face of infection with FIP virus (FIPV). Previous experimental FIPV infection studies suggested a role for cell-
mediated immunity in resistance to development of FIP. This experimental FIPV infection study in specific pathogen
free (SPF) kittens describes longitudinal antiviral T cell responses and clinical outcomes ranging from rapid progression,
slow progression, and resistance to disease.
Results: Differences in disease outcome provided an opportunity to investigate the role of T cell immunity to FIP
determined by T cell subset proliferation after stimulation with different viral antigens. Reduced total white blood cell
(WBC), lymphocyte and T cell counts in blood were observed during primary acute infection for all experimental groups
including cats that survived without clinical FIP. Antiviral T cell responses during early primary infection were also similar
between cats that developed FIP and cats remaining healthy. Recovery of antiviral T cell responses during the later phase
of acute infection was observed in a subset of cats that survived longer or resisted disease compared to cats showing
rapid disease progression. More robust T cell responses at terminal time points were observed in lymph nodes compared
to blood in cats that developed FIP. Cats that survived primary infection were challenged a second time to pathogenic
FIPV and tested for antiviral T cell responses over a four week period. Nine of ten rechallenged cats did not develop FIP or
T cell depletion and all cats demonstrated antiviral T cell responses at multiple time points after rechallenge.
Conclusions: In summary, definitive adaptive T cell responses predictive of disease outcome were not detected during
the early phase of primary FIPV infection. However emergence of antiviral T cell responses after a second exposure to
FIPV, implicated cellular immunity in the control of FIPV infection and disease progression. Virus host interactions during
very early stages of FIPV infection warrant further investigation to elucidate host resistance to FIP.
Keywords: Feline infectious peritonitis, Feline infectious peritonitis virus, Antiviral T cell responsesBackground
Naturally occurring feline infectious peritonitis (FIP) is
invariably fatal once clinical signs appear [1]. However,
mortality due to feline infectious peritonitis virus (FIPV)
infection may not be nearly as severe as reports in the
field indicate, because many infected cats may not show© The Author(s). 2019 Open Access This artic
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the Creative Commons license, and indicate if
(http://creativecommons.org/publicdomain/ze
* Correspondence: farina@upm.edu.my; eesparger@ucdavis.edu
1Department of Medicine and Epidemiology, University of California, One
Shields Avenue, Davis, CA 95616, USA
Full list of author information is available at the end of the articleovert clinical disease and therefore escape diagnosis. The
proportion of naturally infected cats that are resistant to
disease is difficult to estimate, although it is probably
similar to the proportion of random bred cats that fail to
develop FIP after experimental infection. Depending on
the strain of FIPV and the route of inoculation used for
experimental infection, up to 36% of random bred cats
will resist disease [2]. The nature of this immunity is
unknown, although humoral immunity is known to be
non-protective and contributory to the disease signs [3].le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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munity to FIPV is largely cell-mediated [4–8]. The poten-
tial role of cellular immunity in FIP was also inferred from
experiments with cats rendered immunocompromised by
chronic experimentally-induced feline immunodeficiency
virus (FIV) infection. Twenty percent of FIV-infected cats
developed FIP upon infection with feline enteric corona-
virus (FECV), the parental virus to FIPV, whereas none of
the FIV naive siblings became ill [9]. This study suggested
that although the FECV to FIPV mutation is quite com-
mon in nature, FIP is unlikely to develop in older cats in
the face of a normal T-cell immunity.
The first study reporting virus-specific immune re-
sponses in cats with recurrent FIPV infection revealed that
multiple epitopes within the spike (S) protein encoded by
FIPV, were targeted by both CD4 and CD8 T cells [6].
However, the predominant response was observed in CD8
T cells, particularly in cats that survived a type II FIPV-
79-1146 infection. Later reports based on experimental in-
fection with type II FIPV-79-1146 and type I FIPV-KU2 in-
oculation demonstrated that expression of interferon-
gamma (IFN-γ) by antiviral T cells was associated with re-
sistance to the development of FIP [7, 8]. These studies
also identified multiple epitopes encoded within the S-2
domain of the viral spike protein and the N protein that
were associated with Th1 responses and resistance to the
development of FIP. In spite of these and other studies, the
body of evidence suggesting the importance of virus-
specific T cell responses in resistance to FIPV-associated
disease remains small, especially for pathogenic type I FIPV
isolates. Given that type I FIPV is the most common feline
coronavirus in the field, additional studies characterizing
virus-specific cellular immune responses during type I
FIPV infection seem particularly warranted [10–14] .
This report describes the characterization of antiviral T
cell responses of multiple cohorts of cats involved in experi-
mental FIPV infection studies. One group of cats developed
FIP following experimental primary FIPV infection with
disease distinguished by two different outcomes including
rapid or slow progression. A small proportion of cats within
the same experimental infection study, proved resistant to
disease demonstrating a third possible outcome during pri-
mary experimental FIPV infection. A cohort of cats resist-
ant to development of FIP during primary infection were
re-inoculated with FIPV to examine resistance and cellular
immune responses associated with a secondary virus chal-
lenge. Antiviral T cell responses observed for these different
infection outcomes were compared to characterize possible
virus-specific T cell immune correlates for resistance to the
development of FIP. Although a unique antiviral T cell re-
sponse during early acute infection could not be correlated
with resistance or susceptibility to FIP, differences in
antiviral T cell responses were observed for primary versus
rechallenge exposures to FIPV.Methods
Ethics statement
Specific pathogen-free (SPF) cats were obtained from
the breeding colony of the Feline Nutrition and Pet Care
Center, School of Veterinary Medicine, University of
California, Davis, CA. Animals were housed and main-
tained according to regulations and guidelines of the
University of California Davis Institutional Animal Care
and Use Committee (UC Davis IACUC approval num-
bers 15,309 and 16,637).
Cats and FIPV infection
Virus naive SPF cats (n = 19) aged five to six months and
designated as a primary infection group were inoculated
by the oro-nasal route with FIPV-i3c2, a tissue-derived
isolate from experimental cats infected with field virus as
previously described [15]. Virus inoculum contained
semi-purified cell-free supernatants of finely ground dis-
eased tissues including omentum from FIPV-i3c2-infected
cats. Each cat received an inoculum containing 1ml of a
1:5–1:10 dilution of a 25% cell-free suspension which has
proved infectious to 100% of cats based on occurrence of
disease and/or seroconversion. Ten FIPV-resistant cats
aged 8–24months derived from previous experimental in-
fection studies and designated as survivors from con-
firmed primary infections with infectious FIPV-i3c2, were
rechallenged using similar FIPV inocula and infection
route to establish a rechallenge infection group. The
amount of time elapsed between primary FIPV infection
and rechallenge varied for the survivor cat cohort. One
subgroup of the survivor cohort involved six cats that
received a primary inoculation of FIPV-i3c2 by the
oro-nasal route two to six months prior to rechallenge.
Four of these six cats in this subgroup included survivors
derived from the primary infection group described within
this report. A second subgroup included four cats that re-
ceived 1–3 inoculations of FIPV-i3c2 delivered by either
oro-nasal or intraperitoneal routes more than 12months
prior to rechallenge. Twelve uninfected healthy SPF cats
aged five to six months served as controls for these stud-
ies. Each cat was followed from pre-bleed (week 0) until
week 4 post-infection (PI) or the time of euthanasia due to
the development of FIP, with weekly blood samples col-
lected for complete blood count (CBC), T cell counts, and
virus-specific T cell immune response assays. Inoculated
cats were also monitored daily for rectal temperature, fever,
inappetance, depression, diarrhea, dehydration, ascites,
hyperbilirubinuria and jaundice. Cats showing symptoms
of FIP were euthanatized with an intravenous overdose of
pentabarbital/phenytoin. Mesenteric lymph nodes (MLN),
peripheral lymph nodes (PLN) and blood for peripheral
blood mononuclear cells (PBMC) and plasma isolation
were collected in cats undergoing euthanasia due to onset
of FIP and from two healthy uninfected control cats. These
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infection study testing FIPV pathogenesis according to dif-
ferent FIPV variants and prior infection with either FIPV
or FECV [2]. Cats were maintained in housing free of other
feline pathogens and cared for in a uniform manner.
Isolation of PBMC and mononuclear cells from lymph
nodes
PBMC were isolated from blood samples collected from
infected cats at weekly time points by density centrifuga-
tion using Ficoll-Histopaque (Sigma-Aldrich, St. Louis,
MO). Mononuclear cells were isolated from lymph node
tissues (LNMC) harvested post mortem from cats that de-
veloped FIP as previously described [16]. PBMC and
LNMC were incubated overnight in PBMC media [17]
without interleukin (IL)-2 and assayed for T cell pheno-
type and FIPV-specific T cell responses the following day.
T-cell phenotypic analysis
CD3+ lymphocyte (T cell) counts were based on T cell fre-
quencies within PBMC preparations determined by multi-
color flow cytometry and total lymphocyte counts derived
from CBCs. PBMC were assayed for T cell frequency by
staining with either a biotinylated or Alexa Fluor (AF)647-
conjugated anti-human CD3 monoclonal antibody (CD3–
12) (AbD Serotec, Raleigh, NC) specific for a conserved
intracellular epitope shown to be cross-reactive for multiple
species including feline CD3 [18, 19] and analysis by flow
cytometry. Biotinylated CD3 antibody-staining cells were
detected with a strepavidin-phycoerythrin (PE)-Cy7 conju-
gate (Invitrogen, Valencia, CA). Viability of cells acquired
for flow cytometric analysis was assessed using the Live/
Dead® Fixable Aqua stain (Invitrogen). Data were acquired
using an LSRII flow cytometer (BD Biosciences, San Diego,
CA) with 50,000 events obtained for each sample and ana-
lyzed using FlowJo software (TreeStar Inc., Ashland, OR).
Indirect immunofluorescent antibody staining (IFA)
Serum samples collected from FIPV-inoculated cats and
uninfected controls were tested for viral antibody by an
indirect immunofluorescence antibody (IFA) assay as
previously described [20] with commercial slides coated
with FIPV type II-infected cells (VMRD, Pullman, WA).
This assay was performed according to manufacturer’s
recommendation at dilutions of 1:25, 1:100, 1:400,
1:1600 and 1:6400. Slides were assayed using fluores-
cence microscopy (Olympus BX51, Olympus, Center
Valley, PA) and titers were reported based on the highest
dilution up to 1:6400 that yielded detectable fluores-
cence in foci of infected cells.
Virus detection
Two different extraction methods were used for nucleic
acid extraction from cells and tissues in this study. Onemethod for viral nucleic acid extraction from PBMC
used RLT lysis buffer (Qiagen, Valencia, CA) (with beta
mercaptoethanol as per manufacturer’s instructions).
The resulting lysate was protein-digested at 56 °C for 30
min and extracted for RNA and DNA utilizing a com-
mercial kit (Vet-For-All; Qiagen) and a BioSprint 96
magnetic bead extraction (Qiagen) according to the
manufacturer’s protocol. Viral RNA extraction from
plasma (140 μl) also utilized RLT lysis buffer, but RNA
was extracted using the QIAamp Viral RNA Mini kit
(Qiagen). LNMC from mesenteric lymph nodes were
lysed in AB lysis buffer (Applied Biosystems, Grand Is-
land, NY) and RNA extraction was performed using the
ABI Prism 6100 (Life Technologies, Grand Island, NY)
based on protocols previously described [21]. The proto-
col for cDNA synthesis was previously described [22].
FIPV viral loads were assayed in plasma, PBMC, and
LNMC (mesenteric lymph node) by TaqMan real-time
qPCR using a primer probe set based on the conserved
feline coronavirus 7b gene with a minor modification of
the published probe set sequence [23] as follows: AGAG
AAGTTTAAAGATCCGC. TaqMan real-time qPCR was
performed using the 7900 HTFast System AB TaqMan
real-time qPCR. Viral RNA loads in plasma were derived
from a standard curve established with a plasmid (pCR
2.1, Operon) containing the 7b gene target sequence.
Virus loads in PBMC were expressed as viral RNA cop-
ies per million PBMC determined by normalization of
viral copies against feline chemokine receptor (CCR)5
copy number measured for DNA extracted from the
same cell preparation [24]. Based on standard curves
established with the feline coronavirus 7b and feline
CCR5 plasmids, the detection limit for either viral RNA
or CCR5 DNA was 10 copies per reaction. Viral RNA
loads in LNMC were calculated by the 2-ΔΔCt method
[25] normalizing viral RNA expression against feline
glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
expression measured for each LNMC RNA sample.
Viral antigens for T cell immune response assays
A panel of 54 peptides derived from the heptad region
(HR) 1 and inter-helical (IH) region of spike 2 (S2) domain
of the type I FIPV-UCD11 spike protein (accession num-
ber: FJ917519) [26] were used as viral antigens in a
virus-specific T cell proliferation assay (Table 1). Peptides
(Sigma-Aldrich) were synthesized as 15-mer fragments
with an overlap of 11 amino acids. The lyophilized pep-
tides were dissolved in 10% dimethyl sulfoxide (DMSO),
pooled at an approximate concentration of 21.6mg/ml
and stored at − 80 °C. For generation of whole-killed virus
(WKV) antigen, FIPV-UCD 1 [5] virus stocks were pre-
pared from infected Felis catus whole fetus-4 (fcwf-4) cell
(ATCC) cultures. Virus was precipitated from culture su-
pernatants using polyethylene glycol (PEG) and high
Table 1 Amino acid sequences of peptides derived from type 1
FIPV spike protein
Amino acid sequence (start position)
HR1 peptides IH peptides
TSAVAVPFAMQVQARLNY (1055) ITGRLAALNAYVSQTLTQYA (1175)
VALQTDVLQENQKILANA (1073) EVKASRQLAMEKVNECVKS (1195)
FNNAIGNITLALGKVSNSI (1091) QSDRYGFCGNGTHLFSLVN (1214)
TTISDGFNTMASALTKIQS (1110) SAPEGLLFFHTVLLPTEWEE (1233)
VVNQQGEALSQLTSQLQ (1129) VTAWSGICVNNTYAYVLKDF (1253)
KNFQAISSSIAEIYNRLEK (1146) EHSIFSYNNTY (1273)
VEADAQVDRL (1165)
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irradiation for 15min. Western blot and infectivity assays
using fcwf-4 cells were performed to confirm the presence
of virus particles and virus inactivation for WKV prepara-
tions respectively.
Virus-specific T cell proliferation assay
Virus-specific T cell proliferation responses in PBMC
and LNMC isolated from FIPV-inoculated cats and
uninfected controls were assessed using a commercial
kit based on bromodeoxyuridine (BrdU) incorporation
(BrdU Flow Kit; BD Biosciences) and a previously de-
scribed protocol [27] with modifications. Briefly, freshly
isolated PBMC and LNMC were plated at 106 cells per
well in a 24 well plate in standard PBMC media without
IL-2 and cultured (rested) overnight at 37 °C. The next
day cells were stimulated with 2 μg WKV or an
overlapping peptide pool derived from spike HR1 and
IH regions with a working concentration of 2 μg/ml. Un-
stimulated cells cultured in PBMC media without IL-2
served as a negative control. Cells were incubated with
10 μM BrdU for 24 h prior to harvesting and then
stained for BrdU incorporation using a commercial
anti-BrdU antibody labeled with allophycocyanin (APC)
(BD Biosciences) according to manufacturer’s instruc-
tions. For cell surface markers, cells were stained with
anti-feline CD4 (clone 34F4) (Southern Biotech,
Birmingham, AL) conjugated to Pacific Blue using a
commercial kit (Molecular Probes, Grand Island, NY)
and anti-feline CD8- PE (clone vpg9) (AbD Serotec) and
assessed for viability with Live/Dead® Fixable Aqua stain
(Invitrogen). Cells were fixed and permeabilized accord-
ing to manufacturer’s instructions and next stained for
intracellular CD3 expression using anti-human CD3-
fluorescein isothiocyanate (FITC) (clone CD3–12) (AbD
Serotec) and BrdU incorporation with an APC-labeled
anti-BrdU antibody (BD Biosciences). Data were acquired
using an LSRII flow cytometer (BD Biosciences) and
100,000 events were collected and analyzed for each sam-
ple using FlowJo software (TreeStar, Inc). Frequencies forviral immunogen-stimulated proliferation were adjusted
by subtraction of frequencies measured for unstimulated
control PBMC preparations for each sample to yield a
final value for frequencies of antigen-specific T cells.Statistical analysis
Statistical analysis comparing trends for differential blood
and T cell counts determined for cats during primary and
rechallenge infection over time was based on linear mixed
effects regression models using random effects for subject
to account for repeated measures (R, 2.11.0). A Kruskal
Wallis test was used to compare lymphocyte and T cell
counts between three different disease outcomes during
primary FIPV infection (GraphPad Software, Inc., San
Diego CA). Pair-wise analysis was performed to compare
median frequencies of proliferating CD4 and CD8 T cells
after stimulation with viral immunogens using the
Mann-Whitney U test (one-tailed) also using GraphPad
Prism. P values < 0.05 were considered significant.Results
Disease outcome
Nineteen naive SPF cats were inoculated oronasally with
the FIPV-i3c2 isolate and monitored for illness up to
106 days post-infection. Fifteen cats (79%) succumbed to
FIP during primary infection while the remaining four
cats (21%) were still healthy without fever or clinical
signs of FIP until the end of the study (106 days PI) and
designated FIP resistant or survivors. The median sur-
vival for those cats that developed FIP during primary
FIPV-i3c2 infection was 43.5 days. Eleven of the 15 dis-
eased cats (73%) manifested the effusive form (wet) of
FIP characterized by ascites and inflammation of intes-
tinal serosa and 4/15 (27%) developed the non-effusive
(dry or wet-dry) form characterized by granulomatous
lesions in abdominal organs, central nervous system, or
both tissues. Eight of 11 cats with effusive FIP died
within 30 days and were deemed rapid progressors
(Table 2). Three cats with effusive FIP and the four cats
with non-effusive FIP survived past 30 days and were
designated slow progressors (Table 2). Overall, 8/19
(42%) of the experimentally infected cats were classified
as rapid progressors, 7/19 (37%) slow progressors, and
4/19 (21%) as FIP resistant (survivors). Ten cats that sur-
vived primary infection with FIPV-i3c2, including four
survivor cats from this acute infection study, were chal-
lenged again with the same FIPV isolate. One out of the
ten (10%) cats succumbed to FIP within three weeks of
rechallenge (Table 3). Importantly, the remaining nine
cats within the rechallenge group did not develop FIP
based on the absence of FIP-associated symptoms after a
secondary exposure to virus.
Table 2 Summary of findings for primary FIPV infection
Cat ID Onset of fever (dpi) Time of euthanasia (dpi) FIP form Antibody titer Progressor type Virus load
11–163 2 9 Wet 1:25 Rapid BLD
11–165 7 11 Wet 1:100 Rapid BLD
11–224 13 15 Wet 1:100 Rapid 6.1 × 102 PBW1
11–226 13 15 Wet 1:25 Rapid BLD
11–227 15 24 Wet 1:100 Rapid 4.8 × 104 P W2
11–150 28 29 Wet 1:400 Rapid BLD
11–162 28 29 Wet 1:400 Rapid 8.7 × 104 P W2
11–230 28 30 Wet < 1:25 Rapid 4.1 × 104 P TB
11–152 25 42 Wet-dry 1:400 Slow 4.3 × 102 PBW2
3.5 × 102 PBW3
11–228 40 45 Dry 1:100 Slow BLD
11–229 39 45 Wet-dry 1:400 Slow BLD
11–231 46 48 Wet 1:100 Slow BLD
11–164 35 49 Wet 1:1600 Slow 1.5 × 106 P W2
6.1 × 103 PBW2
11–151 39 50 Wet 1:400 Slow BLD
11–148 28 106 Dry 1:6400 Slow 2.5 × 104 PBW2
3.9 × 102 PBW3
11–147 NA NA NA 1:100 FIP resistant 3.1 × 104 P W2
11–149 NA NA NA 1:100 FIP resistant 3.2 × 105 P W2
1.8 × 102 PBW2
11–166 NA NA NA 1:100 FIP resistant BLD
11–225 NA NA NA 1:400 FIP resistant BLD
The abbreviation dpi represents days post inoculation. Antibody titers represent the time point of euthanasia or 4 weeks post inoculation for survivor cats. Virus
load represents measurements in PBMC and plasma only. BLD denotes below the limits of detection. PB represent PBMC and the associated value shown
represents FIPV RNA copies per 106 cells. P denotes plasma and the associated value represents FIPV RNA copies per ml. W with associated number value stands
for week PI and TB stands for terminal bleed. Virus load detection results in LNMC are reported in the text
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Differential blood cell counts and T cell frequencies were
examined longitudinally following primary and second-
ary infections. Total white blood cell (WBC) counts de-
creased significantly following primary infection (P <
0.001) when compared to healthy age-matched controls
(Fig. 1A). The decline in total white cells during acute
primary infection was not associated with a decline in
neutrophils (Fig. 1B) but rather to a significant decrease
in total lymphocyte and T cell counts when compared to
uninfected controls, (P < 0.001) and (P = 0.01) respect-
ively (Fig. 1C-D). However, WBC and absolute lympho-
cyte and T cell counts did not significantly decline in
survivor cats after a second inoculation with FIPV-i3c2
during a rechallenge infection (Fig. 1A, C-D). Interest-
ingly, differences in the magnitude of lymphocyte or T
cell depletion were not associated with disease course as
survivors showed declines similar to those observed in
rapid and slow progressors for both parameters over the
four week time period following primary inoculation
(Fig. 2). Significant differences in either lymphocyte or T
cell counts were not observed between these three ani-
mal groups stratified by outcome during acute primaryinfection based on analysis by a Kruskal Wallis test con-
ducted for weeks 0–4.
Antiviral antibody responses
Antibody titers ranged from < 1:25 to 1:400 for all cats that
developed FIP, except for two cats that survived 49 days
and 106 days and demonstrated terminal titers of 1:1600
and 1:6400, respectively (Table 2). Titers ranging from
1:100 to 1:400 at four weeks PI were observed for the four
cats that did not develop FIP during primary FIPV infec-
tion. Interestingly, all four survivor cats from the acute
infection group (11–147, 11–149, 11–166, 11–225) demon-
strated a higher anti-FIPV antibody at the time of rechal-
lenge (Table 3), compared to titers observed at week 4 of
acute infection for these same cats (Table 1), suggesting
persistent viral antigen exposure despite resistance to devel-
opment of FIP. All survivor cats demonstrated a four-fold
increase of antiviral antibody over a four week period after
rechallenge with FIPVi3c2 (Table 3).
Virus detection
Virus detection or virus loads in blood did not correlate
with development of FIP based on viral RNA concentrations
Table 3 FCoV antibody titer after FIPV rechallenge
Cat ID Antibody titer after primary infection Antibody titer after rechallenge infection
10–068 1:25 1:100
10–084 1:100 1:400
10-143a 1:25 1:100
10–145 1:25 1:100
11–073 1:400 1:1600
11–074 1:400 1:1600
11–147 1:1600 1:6400
11–149 1:400 1:1600
11–166 1:1600 1:6400
11–225 1:1600 1:6400
aCat died as a result of FIP at week 3 post FIPV rechallenge. For all other cats, antibody titers after rechallenge represent 4 weeks after re-inoculation with virus
whereas titers after primary infection represent day 0 of the rechallenge study
Fig. 1 Comparison of differential cell counts including T cell counts in different FIPV infection cohorts. A linear mixed regression analysis of differential
blood leukocyte counts compared WBC (a), neutrophil (b), lymphocyte (c) and T cell (d) counts between primary, rechallenge FIPV infections and
uninfected SPF cats. Cell counts were determined at weekly time points until euthanasia or the end of the study (week 4 PI). T cell counts were calculated
by percentage of CD3+ cells within the total PBMC gate detected by flow cytometry and absolute lymphocyte counts. Symbols represent cell count
values for individual cats and dotted lines represent the fitted slope for each cat cohort. Each P value represents a comparison of slopes between primary
infection and the uninfected control group. Asterisks *** reflect values for P< 0.001, ** reflect P values < 0.01, and * reflects P values < 0.05
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Fig. 2 Lymphopenia and T cell depletion associated with different disease outcomes for primary infection. Median values for lymphocyte and T
cell counts calculated for rapid progressors, slow progressors, and survivors are plotted for weekly time points of primary infection. Significant
differences were not detected for lymphocyte or T cell counts between different disease outcomes at each time point based on analysis by a
Kruskal Wallis test
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3/7 (43%) slow progressors, and 2/4 (50%) survivors (Table
2). Virus was detected most frequently at two weeks PI with
7/9 (78%) viremic cats showing circulating virus in either
plasma, PBMC or both, at this time point. In contrast, circu-
lating virus was detected in one cat at one week and two
cats at three weeks PI. Circulating virus was also detected in
one rapid progressor at a terminal time point bleed (TB).
Frequency of virus detection in PBMC (5/9) (56%) of
viremic cats was comparable to that observed to plasma (6/
9) (67%). However, virus loads tended to be higher in
plasma, ranging from 3.1 × 104 to 1.5 × 106 copies per ml of
plasma compared to 1.8 × 102 to 2.5 × 104 copies per million
PBMC. Viral loads of 3.1 × 104 and 3.2 × 105 copies per ml
were detected in plasma from two survivor cats, indicating
that viral loads in plasma or PBMC were not associated with
disease or resistance. Preparations of MLN were collected at
post mortem from 13/15 cats with FIP and all samples
tested were positive for viral RNA with delta CT (FIPV CT
– GAPDH CT) values ranging from 7.44 (lower loads) to
− 4.2 (highest virus load) (data not charted). Virus loads for
MLN showed significant variability but no correlation with
rapid or slow disease progression. Virus was also detected in
MLN (3.7 × 104 copies million cells) and PBMC (3.9 × 103
copies million cells) drawn at the terminal time point from
the single cat that developed FIP upon a secondary exposure
to FIPV-i3c2. Otherwise, virus was not detected in PBMC
or plasma from the nine cats that remained healthy after
secondary challenge with FIPV-i3c2.
Virus-specific T cell proliferation responses in peripheral
blood during primary infection
T cell proliferation responses following specific antigen
stimulation and based on BrdU incorporation were
assayed longitudinally and compared for cats with rapid
disease, slower progressive FIP, and resistance to FIP.
Due to protocol limitations on the blood volumes sam-
pled and infection-associated lymphopenias, antiviral Tcell response assays were not consistently available for
each cat at every time point. Representative scatter plots
for assay of T cell proliferation following antigen stimu-
lation are shown in Fig. 3A. No significant differences
for CD4 or CD8 T cell proliferative responses to either
viral immunogen were observed at weeks 1–4 after virus
inoculation between cats that either succumbed to, or
resisted the development of FIP (Fig. 3B-C). Compari-
sons between cats that died or resisted disease following
primary infection were limited by the low number of
survivors (n = 4) and the number of surviving cats (2–3)
assayed at each time point. Similarly, only three rapid
progressors were tested at four weeks PI due to deaths
of rapid progressors at earlier time points. Despite these
limitations, certain trends in antiviral immune responses
were demonstrated between the three groups of cats.
The emergence of CD8 T cell responses to WKV was
detected more frequently in slow progressors (4/5
tested) and survivors (2/3 tested) at one week PI com-
pared to rapid progressors (2/7 tested) (Fig. 3C). By two
weeks PI, a higher proportion (4/5) of rapid progressor
cats showed relatively strong CD4 T cell responses to
WKV whereas 3/5 slow progressors and 1/3 survivors
demonstrated detectable CD4 T cell responses at this
time point (Fig. 3B). In contrast, detection of CD8 T re-
sponses to WKV and CD4 and CD8 T cell responses to
viral peptides was infrequent at this time point for all
groups. The proportion of cats showing detectable CD4
and CD8 T cell responses to either WKV or peptide by
week 3 PI was very low or negligible for all three groups
of cats, coinciding with a persistent T cell loss in per-
ipheral blood first observed at week 2 PI. However, by
four weeks PI, a recovery of antiviral T cell responses
including both CD4 and CD8 T cells, were observed for
selected slow progressors and survivors (Fig. 3B-C).
CD4 and CD8 T cell responses were very low or negli-
gible for rapid progressors at week 4 of infection with
the exception of one cat.
AB
C
Fig. 3 Antiviral T cell proliferative responses during primary FIPV infection. Representative FACS plots comparing unstimulated to WKV and viral
peptide stimulation in CD3 + CD4+ T cells are shown (a). PBMC were assessed for viability by live/dead exclusion and interrogated by staining for
CD3, CD4 or CD8 as described in Methods. T cell subsets were then assayed for proliferation responses to different viral immunogens based on
positive staining for BrdU using an anti-BrdU monoclonal antibody. A comparison of the frequencies of CD4 and CD8 cells showing proliferation
after stimulation with WKV or FIPV peptide stimulation is shown for rapid progressors, slow progressors and survivors (FIP resistant cats) before
and after FIPV inoculation (b). Horizontal lines represent median values for each group. Significant differences were not detected for T cell
frequencies between different disease outcomes at each time point based on a pair-wise analysis by one-tailed Mann-Whitney U test
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blood during rechallenge infection
A cohort of cats surviving previous challenge with
FIPV-i3c2 allowed examination of memory antiviral T
cell responses induced by re-exposure to the same
pathogenic FIPV isolate and the comparison of such re-
sponses to those associated with primary infections
(Fig. 4A). A small subset of survivor cats revealed detect-
able baseline CD8 T cell responses to peptides (Fig. 4A).
Otherwise, circulating CD4 T cell responses to both pep-
tides and WKV, and CD8 responses to WKV, were lowor negligible prior to rechallenge. CD4 T cell prolifera-
tion responses to viral peptides were significantly differ-
ent between primary and rechallenge infections for
weeks 2 (P = 0.034), 3 (P = 0.015) and 4 (P = 0.037) where
higher CD4 T cell responses were observed for rechal-
lenged survivor cats. CD8 T cell responses to WKV and
viral peptides were also higher for rechallenge infections
for week 3 (P = 0.032 and P = 0.011 respectively). As
mentioned above, significant declines in circulating
lymphocyte and T cell counts were observed during pri-
mary infection likely impacting antiviral T cell responses
AB
C
D
Fig. 4 Comparison of antiviral T cell proliferative responses between primary and rechallenge FIPV infections. Frequencies of CD4 and CD8 T cells
showing proliferation after stimulation with either WKV or FIPV peptides during primary FIPV infection with cats from all outcomes included, were
compared to responses during rechallenge infection (a). Horizontal lines represent median values for each group. Frequencies of CD4 and CD8 T
cells showing proliferation after stimulation with either viral immunogen were compared between cats rechallenged with FIPV-i3c2 within 6
months of the primary challenge (< 1 yr. rechallenged) and cats that had been inoculated more than 1 year prior to FIPV rechallenge (> 1 yr.
rechallenged) (b). Numbers shown above any time-point data represent P values calculated using a one-tailed Mann-Whitney U test (GraphPad
Prism) to compare median T cell proliferation frequencies determined for primary versus rechallenge infections for each time point (a) or
determined between rechallenge infection groups for each time point of rechallenge infection (b). P values < 0.05 were considered significant
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T cell counts were not associated with rechallenge infec-
tion. It is noteworthy that cats within the primary infec-
tion group showing responses similar to the highest
responders in the rechallenge group at the week 4 time
point tended to be slow progressor or survivor cats (Fig.
3B-C and Fig. 4A).
Based on the wide range of T cell responses observed
for rechallenge infection, this group was further strati-
fied into two cohorts based on timing of the previous
exposure to FIPV-i3c2 (Fig. 4B). Cats that were rechal-
lenged with FIPV within 2–6 months after primary infec-
tion showed greater CD4 and CD8 T cell responses at
one week after rechallenge compared to cats infected
one year or more before rechallenge (Fig. 4B). However,
this observation was only significant for CD4 T cell
responses to WKV (P = 0.03). T cell responses were
comparable between both groups of cats at weeks 2–4
during rechallenge infection, regardless of time duration
between primary and rechallenge infections. Import-
antly, all cats within the rechallenge infection group
demonstrated antiviral T cell responses for multiple time
points after a secondary FIPV exposure.
Virus-specific T cell proliferation responses in blood and
lymph nodes associated with FIP
The final analysis of this study compared antiviral T cell
responses between LNMC harvested from MLN and
PLN with PBMC collected at the time of euthanasia due
to onset of FIP. PBMC and LNMC were similarly
assayed for virus-specific CD4 and CD8 T cell prolifera-
tion responses to both viral immunogens, although data
for PLN were not available for all cats undergoing post
mortem exam. A longitudinal assessment of lymph node
T cell responses over time after infection was possible due
to temporal differences in the disease course for different
cats with FIP. Assay of lymph node T cell responses from
two different cats at the same time point of primary infec-
tion (15, 29, and 45 days PI) were also available. Responses
from both rapid and slow progressors were compared
with each other with LNMC harvested from age-matched
healthy control cats serving as negative controls. CD4 and
CD8 antiviral T cell proliferative responses varied between
different tissues within individual cats, between different
cats, and between different time points (Fig. 5A). How-
ever, CD4 and CD8 T cell responses of the highest magni-
tude (> 1% proliferating T cells) were observed for MLN
(9, 29, 30, 45, 48, 49, and 50 day PI) and blood (15 days PI)
when tested against either WKV or viral peptides (Fig.
5A). CD4 and CD8 T cell responses to peptides were
usually low or negligible for PBMC, with the exception of
PBMC harvested at 9 and 15 days PI from two rapid pro-
gressor cats. Overall, higher MLN CD4 and CD8 T cell
responses to WKV were observed in cats that developedFIP after 24 days of primary infections suggesting an asso-
ciation of more robust T cell responses at this particular
site with longer survival, although differences between
rapid and slow progressors were not statistically signifi-
cant. Also of importance was a frequent lack of a compar-
able magnitude in antiviral T cell responses between PLN
and MLN from the same cat suggesting that a PLN may
not serve as a surrogate site for assay of host MLN re-
sponses. However, a trend for PLN CD8 T cell responses
to WKV of greater magnitude was observed for rapid pro-
gressors (n = 5) at terminal time points compared to PLN
responses observed for slow progressors (n = 3) (Fig. 5B),
although the difference was not statistically significant (P
= 0.071).
Discussion
Although multiple reports have described immune re-
sponses associated with FIPV infection, immune corre-
lates that protect infected animals from this fatal disease
remain poorly understood. Previous studies investigating
antiviral T cell responses induced by experimental infec-
tion with either FIPV79–1146 or FIPV KU-2, were lim-
ited to a single time-point after infection and provided
evidence supporting the role of T cell immunity in resist-
ance to FIP [6–8]. This report describes the first longitu-
dinal study of virus-specific T cell responses in cats
experimentally infected with a highly pathogenic type 1
FIPV isolate (FIPV-i3c2). The aim of this study was to
identify possible antiviral T cell correlates for disease
outcome during acute infection and after rechallenge of
FIP-resistant cats with the same FIPV isolate. Two ap-
proaches were used to characterize such correlates in-
cluding a comparison of T cell immune responses in cats
that either exhibited a rapid or slow progression to FIP,
or did not develop FIP during primary infection with
FIPV-i3c2. A second approach involved comparison of T
cell responses in cats during primary FIPV-i3c2 infection
with responses elicited after a rechallenge exposure of
cats that survived a primary FIPV challenge. A reason-
able hypothesis for host factors responsible for absence
of FIP would be the emergence of circulating antiviral T
cell responses of significantly higher magnitude during
the first two weeks of infection. However, our findings
did not reveal a definitive correlation for emerging anti-
viral T cell responses during very early stages of primary
infection and disease outcome. Nevertheless, a recovery
of antiviral T cell responses at a later time point of
primary infection and emergence of antiviral T cell
responses in FIP-resistant cats after a second exposure
to FIPV suggested that cellular immunity may be associ-
ated with some level of control of FIPV infection result-
ing in a delay or absence of disease progression.
Both WKV and S2 peptides proved capable of evoking
CD4 and CD8 T cell proliferative responses in cats
AB
Fig. 5 Comparison of antiviral T cell proliferative responses in different lymphoid compartments in cats with FIP. Data plotted for each time-point
PI on each graph represent T cell responses (frequencies of proliferating cells) detected for LMNC isolated from either a peripheral lymph node
(PLN) or mesenteric lymph node (MLN) and for PBMC (blood) from an individual animal euthanized at that particular time-point due to FIP with
terminal time-points representing 14 cats up to 106 days PI. The vertical dotted line for each graph divides time-points of euthanasia for cats
showing rapid versus slow progression of disease. Controls represent T cell responses measured in similar lymphoid tissues and blood harvested
from healthy uninfected age-matched SPF cats (n = 2). Responses for both T cell subsets for two different FIPV immunogens (WKV and viral
peptides) are also shown (a). Values for T cell responses associated with PLN measured in cats showing rapid progression were compared to
those detected for cats showing slower progression of disease and measured at later time points of infection (b). Numbers shown for each
comparison represent P values calculated using a one-tailed Mann-Whitney U test (GraphPad Prism). P values < 0.05 were considered significant
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valuable tool for a longitudinal investigation of antiviral T
cell responses during primary and rechallenge infections.
Limitations to these studies included the low number of
survivor cats during primary infection and assessment of T
cell responses restricted to blood only, for early time points
of primary infection. In contrast, lymph node and circulat-
ing T cell responses were compared at terminal time points
in cats that progressed to disease. A comparison of
responses in abdominal lymphoid tissues at earlier time
points of infection for both progressors and survivors
would be more informative based on the typical localization
of FIPV replication to the abdominal cavity. Despite these
limitations, examination of antiviral T cell responses in
blood during primary infection revealed certain trends and
critical observations. An earlier emergence of both CD4
and CD8 T cell responses observed for slow progressors
and survivors at one week after virus inoculation con-
trasted to a delay of one week in responses emerging in
some cats with rapidly progressive disease. Regardless ofthese temporal differences in early responses, the magni-
tude of T cell responses did not differ significantly be-
tween cats with different disease outcomes during the first
three weeks of early infection and almost all cats showed
negligible responses by three weeks into infection. How-
ever, by four weeks after infection, a proportion of slow
progressors and survivors were distinguished from rapid
progressors in their recovery of antiviral T cells responses.
Collectively, these findings suggested that circulating anti-
viral T cell responses during very early time points of
acute infection do not predict disease outcome. Yet, re-
covery of circulating antiviral T cell responses later in
acute infection may be associated with a delay in disease
or absence of disease. These findings lend some support
to the widely-held hypothesis that FIP results from a fail-
ure of T cell immunity [1], but also suggest that other un-
determined virus host interactions or antiviral responses
are critical for an outcome of FIP.
Robust CD4 and CD8 T cell responses were more fre-
quently demonstrated in MLN harvested from more cats
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PLN harvested at earlier time points of primary infection
tended to be of higher magnitude compared to PLN
responses observed for slow progressors. Also, PLN-
associated T cell responses frequently did not match
MLN responses from the same host, particularly for cats
surviving 29 days or later. These findings suggest that
MLN may represent a major site for T cell-mediated
control of virus replication and disease progression and
FIPV responses in both disease and antiviral immunity.
This finding may not be surprising based on previous re-
ports showing virus replication in systemic lymphoid tis-
sues including MLN [28–30] and a relative absence of
detectable virus in PLN [31]. Furthermore, previous re-
ports revealed that the mildest form of FIP disease was
limited to the MLN, and that some cats with this
form of disease will proceed to recovery further sug-
gesting a role for antiviral immunity at this tissue site.
Conversely, dissemination of virus infection from
MLN to other sites within the host is associated with
disease progression [1, 32].
The most striking abnormalities observed during pri-
mary FIPV infection were a progressive decline in WBC,
lymphopenia, and T cell depletion, which most likely im-
pacted host responses to the virus infection during the
early phases of acute primary infection. This is not a new
observation and was described in other reports of natural
and experimental FIPV infections in cats developing FIP
[6, 31, 33, 34]. An unexpected finding was the observation
of similar profound changes in the T cell compartment in
cats that survived the infection with no outward signs of
disease during primary infection. A comparable finding of
T cell depletion was also reported for cats that recovered
without FIP after infection with pathogenic type 2 FIPV
79–1146 [6]. However, findings also reported by our group
for one survivor and one rapid progression for FIPV-m3c2
from a different study revealed lymphopenia demon-
strated only by the rapid progressor [30]. Whether differ-
ences specific to the FIPV isolate, route of inoculation
(intraperitoneal inoculation for FIPV-m3c2 study) or other
unknown variables accounted for the lymphopenia and T
cell depletion observed in this study for survivors remains
to be determined. The T cell depletion observed for all
FIPV-i3c2-infected cats regardless of subsequent disease
progression provides one compelling explanation for the
demise of detectable circulating antiviral T cell responses
by three weeks into primary infection for all cats and a
failure to characterize cellular immune responses associ-
ated with survival.
A recent experimental FIPV infection study by our
group revealed that sustainable immunity is not always
maintained upon multiple exposures of the virus sug-
gesting a distinct antiviral T cell response may confer re-
sistance to FIP among survivor cats [2]. Rechallenge ofsurvivor cats with the same pathogenic FIPV as de-
scribed in this report, offered an important opportunity
to examine the magnitude of T cell responses after a sec-
ondary exposure to FIP and to also compare such re-
sponses to those associated with primary infection.
Moreover, this rechallenge study determined whether
survivor cats would be capable of maintaining resistance
to a second challenge with pathogenic FIPV-i3c2. Re-
sults revealed that nine out of ten cats surviving a pri-
mary infection remained resistant to FIP after a
secondary exposure to infectious FIPVi3c2, regardless of
the span of time between primary and second challenge
with FIPV. In contrast, only one survivor cat subse-
quently developed FIP. Antiviral T cell responses noted
after FIPV rechallenge were variable in magnitude, par-
ticularly at one week PI where variability was associated
with the duration of time between the primary and sec-
ondary infections. Irrespective of variability between
cats, all rechallenge infections were associated with re-
appearance of antiviral T cell responses with detection of
T cell responses observed for 2–3 time points after re-
challenge. In addition, rechallenge infection showed
greater antiviral T cell responses for multiple time points
after FIPV rechallenge including week three, compared
to primary infection responses. This finding is note-
worthy because the week three time point in primary in-
fection was characterized with ablated antiviral T cell
responses and significant T cell depletion for all cats in-
cluding slow progressors and survivors. Furthermore,
cats that survived an earlier infection with FIPV not only
failed to develop clinical symptoms of FIP but also dem-
onstrated very mild or no lymphocyte and T cell deple-
tion after rechallenge with pathogenic FIPV-i3c2. The
absence of severe lymphoid depletion and other clinical
signs of FIP in survivor cats during rechallenge infection,
along with detection of antiviral T cell responses over
multiple time points including three weeks PI, implies a
role for cellular immunity in the resistance to FIP after a
secondary exposure to the virus. It should be noted that
the survivor cat that developed FIP after rechallenge
demonstrated antiviral T cells responses during early time
points post rechallenge but responses were absent by 3
weeks post rechallenge, the final time point for this cat. Per-
sistence of antiviral T cell responses has been demonstrated
in human patients recovered from the Severe Acute Re-
spiratory Syndrome (SARS) coronavirus (SARS-CoV) [35,
36]. However, antiviral humoral responses including neu-
tralizing antibody, as well as other types of host responses
must also be considered as possible factors for this resist-
ance to disease after a secondary exposure to FIPV.
Viremia was not an accurate predictor of disease out-
come and was observed in either plasma or PBMC in
approximately 50% of cats that either died or survived
primary infection, with circulating virus most frequently
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the emerging lymphocyte and T cell depletion and com-
pares well to results of experimental studies with patho-
genic Type 2 FIPV 79–1146 where viremia was typically
restricted to 4–12 days PI, when detected [6, 8]. Viral
RNA was consistently detected in mesenteric lymph nodes
at post mortem for cats with FIP, which confirmed this tis-
sue as a consistent site for virus replication. This is in
agreement with findings in another study measuring the
levels of FIPV in various tissues where high levels of virus
were detected in diseased tissues particularly the omen-
tum and MLN, but not in blood [30]. In contrast, survivor
cats did not develop a detectable viremia after rechallenge
with FIPV-i3C2, with the exception of the one cat that de-
veloped FIP after a secondary exposure and tested positive
for viral RNA in blood and mesenteric lymph node at post
mortem. Increases by four-fold in antiviral antibody titers
and emergence of memory T cell responses observed for
all survivor cats during the four weeks after rechallenge
with FIPV-i3c2 suggested the possibility of some level of
virus replication resulting from the second exposure that
was nevertheless controlled by host responses. Questions
regarding sites of persistent virus replication or virus elim-
ination for cats apparently resistant to FIP after FIPV-i3c2
infection, warrant further investigation including assess-
ment of multiple tissues for viral RNA as described in
companion pathogenesis studies of this virus isolate by
N.C. Pedersen et al. [30].
Taken together, findings from these infection studies did
not reveal definitive immune correlates for resistance, or a
delay in progression to FIP during acute primary infection
with a pathogenic type 1 FIPV, except for a recovery of
antiviral T cell responses at a later time point of infection
for some but not all of the slow progressors and survivors
tested. Intriguing findings were that antiviral T cell
responses, circulating virus loads, or the magnitude of T
cell depletion immediately after a primary exposure to
pathogenic FIPV, did not appear to predict disease resist-
ance in this experimental cohort. However, those cats that
recovered FIPV-specific T cells responses without devel-
oping FIP during a primary infection, proved capable of
resisting a second challenge with FIPV that was associated
with emergence of recall T cell responses.
Critical virus-host interactions very early in infection,
which are responsible for resistance or slow progression to
disease, remain unclear from our experimental primary in-
fection studies. Possible explanations include differences in
the magnitude of disruption of innate responses or specific
alterations of innate factors that have been reported for
both SARS CoV and FIPV. Virus-induced inhibitory mac-
rophages reported for the mouse model for the SARS-CoV
[37] were shown to contribute to reduced dendritic cell
activation with subsequent delay of virus-specific T cell
responses and disease onset. Other inappropriate innateresponses included unregulated proinflammatory cytokine
responses leading either to a cytokine storm as reported for
the SARS CoV [38, 39] or to an overstimulation of B cells
[40] possibly leading to enhancing antibody responses as
described for the classical wet form of FIP [1, 41, 42]. Simi-
lar to SARS, overexpression of inflammatory cytokines in-
cluding IL-6 and tumor necrosis factor (TNF)-α with a
reduced expression of IL-10 have also been reported to be
associated with the development of FIP [42]. Production of
proinflammatory cytokine TNF-α from FIPV-infected mac-
rophages has also been implicated in FIPV-associated lym-
phoenia [43, 44]. Moreover, a recent report revealed that
targeting TNF-α with an anti-feline TNF-α monoclonal
antibody prevented infection in cats experimentally
infected with FIPV [45]. Pro-inflammatory cytokines and
antiviral-related genes such as MX1, viperin and IFNγ
have also been observed in tissues harvested from
FCoV-infected cats with FIP [46]. In addition, recent re-
ports focused on gene expression profiles from mesenteric
or peritoneal macrophages harvested from cats with FIP re-
vealed expression of pattern recognition receptors including
toll, NOD and RIG-like receptors, pro-apoptotic genes, and
genes related to differentiation of M1 macrophages in con-
trast to reduced expression of MCH class II receptor genes
[47, 48]. Lastly, the role of host anti-inflammatory factors
such as regulatory T cells and IL-10 as well as innate factors
such as natural killer cells factors warrant further examin-
ation based on other recent reports [29, 49]. Future studies
will need to simultaneously address both innate and adap-
tive responses within critical tissue sites during very early
stages of infection to answer these critical questions regard-
ing mechanisms of recovery from acute pathogenic FIPV
infection.
Conclusions
Key findings from these studies indicate that circulating
antiviral T cell responses within the first four weeks of
primary infection with pathogenic FIPV isolate, were not
predictive of disease outcome. Furthermore, all cats
developed lymphopenia and T cell depletion during early
FIPV infection regardless of progression or resistance to
FIP. Findings that suggest a role for cellular immunity in
FIPV pathogenesis were a recovery of antiviral T cell
responses at a later time point of primary infection for a
subset of cats showing slow progression or resistance to
disease. T cell responses measured in MLN harvested
post mortem were more robust and more frequent for
cats showing slower progression to FIP. Lastly, second-
ary or recall antiviral T cell responses observed in
FIP-resistant cats after a second exposure to FIPV were
associated with resistance to disease progression as well
as an absence of lymphopenia and T cell depletion.
Overall these findings suggest that antiviral T cell
immunity may contribute to FIPV pathogenesis and
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ing the role of other host factors including innate re-
sponse factors, immunoregulatory responses, and B cell
alterations that may also determine disease outcome.
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